Automate Your Wheel Strategy on LLY
With Tiblio's Option Bot, you can configure your own wheel strategy including LLY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol LLY
- Rev/Share 54.5268
- Book/Share 17.633
- PB 42.189
- Debt/Equity 2.4432
- CurrentRatio 1.3723
- ROIC 0.2631
- MktCap 701390981520.0
- FreeCF/Share 0.5421
- PFCF 1439.6367
- PE 59.8845
- Debt/Assets 0.4309
- DivYield 0.0076
- ROE 0.7692
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | LLY | Erste Group | Buy | Hold | -- | -- | June 5, 2025 |
| Downgrade | LLY | HSBC Securities | Buy | Reduce | $1150 | $700 | April 28, 2025 |
| Initiation | LLY | Cantor Fitzgerald | -- | Overweight | -- | $975 | April 22, 2025 |
| Resumed | LLY | BofA Securities | -- | Buy | -- | $997 | Dec. 10, 2024 |
| Initiation | LLY | Bernstein | -- | Outperform | -- | $1100 | Oct. 17, 2024 |
| Resumed | LLY | Citigroup | -- | Buy | -- | $1060 | Sept. 13, 2024 |
News
NVDA & INTC Behind AMD Downgrade, WFC & LLY Upgrades
Published: April 08, 2025 by: Schwab Network
Sentiment: Neutral
Keybanc downgraded AMD Inc. (AMD) to Sector Weight from Overweight, but it didn't shake the stock's rally alongside the market. Diane King Hall talks about why Nvidia (NVDA) and Intel (INTC) are behind the firm's bearish sentiment.
Read More
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
Read More
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Read More
These 5 S&P 500 Stocks Are Growing Revenue The Most Right Now
Published: April 04, 2025 by: 24/7 Wall Street
Sentiment: Positive
These 5 companies will have minimal impact from the tariffs and could deliver strong results in 2025.
Read More
PFE, MRK, LLY & Other Drug Stocks Down Amid Tariff Jitters
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Negative
Stocks of PFE, MRK, ABBV, LLY and others declined on Tuesday due to uncertainty surrounding Trump's proposed tariffs on pharma imports.
Read More
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Published: April 01, 2025 by: CNBC
Sentiment: Negative
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Read More
Hims & Hers to sell Lilly's Zepbound on its telehealth platform
Published: April 01, 2025 by: Reuters
Sentiment: Positive
Telehealth firm Hims & Hers Health said on Monday it plans to sell Eli Lilly's weight-loss drug Zepbound on its platform.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
Published: March 31, 2025 by: Seeking Alpha
Sentiment: Positive
Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
Read More
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Price Targets Show These 3 Stocks Near the $1 Trillion Mark
Published: March 27, 2025 by: MarketBeat
Sentiment: Positive
Currently, just eight vaunted stocks boast market capitalizations of over $1 trillion. This includes six of the Magnificent Seven stocks, as well as Warren Buffett's Berkshire Hathaway NYSE: BRK.A.
Read More
Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly
Published: March 25, 2025 by: CNBC
Sentiment: Positive
Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors' perception of the health care system is improving.
Read More
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today announced the successful close of the sale of its FXR program, including lead asset FXR314, to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025.
Read More
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
Published: March 24, 2025 by: CNBC
Sentiment: Positive
Eli Lilly plans to release initial results from several late-stage clinical trials on its experimental once-daily obesity pill, orforglipron, this year. The trial results are among the pharmaceutical industry's most critical of the year, as they will bring Eli Lilly's pill one step closer to becoming a new, needle-free alternative for weight loss and diabetes.
Read More
Watch These 5 AI-Powered Healthcare Bigwigs for Portfolio Gains
Published: March 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Five AI-powered stocks have strong revenues and earnings growth potentials for 2025. These are: MDT, LLY, BSX, NVS, ABT.
Read More
Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars?
Published: March 24, 2025 by: Proactive Investors
Sentiment: Negative
Eli Lilly and Co (NYSE:LLY) is tightening its grip on the obesity drug market, with its injectable treatment Zepbound gaining momentum over Novo Nordisk's Wegovy, according to Berenberg. The investment bank says physician feedback in the US is now leaning in Lilly's favour, with many citing better tolerability and efficacy.
Read More
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vials New integration means streamlined ordering and paying experiences for patients, with the same direct shipping and the best self-pay price on single-dose Zepbound vials
Read More
Market Sell-Off: Can Buying These 3 "Safe" Stocks Today Set You Up for Life?
Published: March 24, 2025 by: The Motley Fool
Sentiment: Positive
The U.S. equity market has had a solid run in the past two years, buoyed by a steadily improving macroeconomic environment and strong uptake of artificial intelligence technologies. The benchmark S&P 500 index climbed almost 53% in the past two years.
Read More
5 Reasons It's Not Too Late to Buy Eli Lilly Stock
Published: March 20, 2025 by: The Motley Fool
Sentiment: Positive
Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable healthcare company in the world, with a market cap of $730 billion.
Read More
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Published: March 20, 2025 by: Reuters
Sentiment: Positive
Eli Lilly has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday.
Read More
Eli Lilly: A Safe Harbor Amid Market Volatility
Published: March 17, 2025 by: Seeking Alpha
Sentiment: Neutral
My DCF analysis suggests that Eli Lilly's stock is 60% undervalued. Defensive healthcare stocks like Eli Lilly are favorable in the current uncertain macroenvironment, driven by tariff concerns and stable Fed policies. The company's robust revenue growth, high R&D spending, and strategic positioning in the GLP-1 industry underscore its long-term growth prospects.
Read More
NVO vs. LLY: Which Stock Is the Better Value Option?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Large Cap Pharmaceuticals sector have probably already heard of Novo Nordisk (NVO) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
Read More
Calls of the Day: Shake Shack, Starbucks, 3M, Gilead Sciences, Eli Lilly
Published: March 14, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
Final Trades: Visa, Blackstone, Eli Lilly and Invitation Homes
Published: March 13, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
Published: March 12, 2025 by: Reuters
Sentiment: Neutral
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdered outside the company's investor meeting in December, regulatory filings show.
Read More
Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)
Published: March 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Eli Lilly and Company (NYSE:LLY ) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ET Company Participants Lucas Montarce - CFO Mike Czapar - Head of IR Conference Call Participants Dave Risinger - Leerink Partners Dave Risinger All right. So, I think we should get started here.
Read More
Novo Nordisk Stock Drops on New Obesity Drug Finding. Eli Lilly Stands to Gain.
Published: March 10, 2025 by: Barrons
Sentiment: Negative
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
Read More
About Eli Lilly and Company (LLY)
- IPO Date 1972-06-01
- Website https://www.lilly.com
- Industry Drug Manufacturers - General
- CEO David A. Ricks
- Employees 47000